Then, previous studies have shown that trastuzumab can lead to decreased heart function and heart failure in patients with HER2-positive BC36,37, especially when used in combination with doxorubicin38, which may be the reason for the higher risk of death from HD in HER2-positive breast cancer in our study. The gene discussed is ERBB2; the disease is breast carcinoma.